MedTrace Logo

HEPA, PM2.5, and Cardiometabolic Health

NCT05718245 · Status: RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 52

Last updated 2025-08-01

No results posted yet for this study

Summary

The goal of this randomized, double-blind, crossover trial is to test the hypothesis that a longer-term indoor HEPA filtration intervention can improve cardiometabolic profiles by reducing indoor PM2.5 exposures in at-risk individuals.

Conditions

  • Air Pollution
  • Cardiometabolic Health

Interventions

DEVICE

HEPA filter

HEPA filters with the capacity to reduce PM2.5 levels

DEVICE

Sham filter

sham filters without the capacity to reduce PM2.5 levels

Sponsors & Collaborators

  • Duke University

    collaborator OTHER

  • University of Southern California

    lead OTHER

Principal Investigators

  • Zhanghua Chen, PhD · University of Southern California

  • Junfeng Zhang, PhD · Duke University

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
DOUBLE
Model
CROSSOVER

Eligibility

Min Age
65 Years
Max Age
84 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2023-03-15
Primary Completion
2026-12-31
Completion
2026-12-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05718245 on ClinicalTrials.gov